Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Peter C. Black, H.A.D.M. Ashab et al.|European Urology|2017Cited by 793
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Núria Porta et al.|The Lancet Oncology|2019Cited by 643
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Peter C. Black et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CancerRoland Seiler, Peter C. Black, Ewan A. Gibb et al.|Clinical Cancer Research|2018Cited by 126